Compare PRLB & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRLB | RAPP |
|---|---|---|
| Founded | 1999 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2012 | 2024 |
| Metric | PRLB | RAPP |
|---|---|---|
| Price | $52.20 | $30.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $53.00 | $47.80 |
| AVG Volume (30 Days) | 147.4K | ★ 417.7K |
| Earning Date | 02-06-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.61 | N/A |
| Revenue | ★ $518,384,000.00 | N/A |
| Revenue This Year | $7.07 | N/A |
| Revenue Next Year | $4.87 | N/A |
| P/E Ratio | $86.10 | ★ N/A |
| Revenue Growth | ★ 2.82 | N/A |
| 52 Week Low | $29.59 | $6.43 |
| 52 Week High | $55.90 | $42.27 |
| Indicator | PRLB | RAPP |
|---|---|---|
| Relative Strength Index (RSI) | 53.48 | 55.51 |
| Support Level | $51.81 | $28.99 |
| Resistance Level | $53.53 | $31.52 |
| Average True Range (ATR) | 1.09 | 1.88 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 54.49 | 54.51 |
Proto Labs Inc is an on-demand manufacturer of custom parts for prototyping and short-run production. The company offers developers and engineers quick-turn production services to reduce the time to market. Proto Labs uses injection molding, computer numerical control machining, and 3-D printing to manufacture custom parts for its clients. The company services clients' needs for prototype solutions, parts for testing procedures, bridge production capabilities during disruptions in manufacturing processes, limited-quantity requests, and end-of-life production support. Geographically, a majority of the company's revenue is derived from the United States and the rest from Europe.
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.